Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486

Aaltomaa, 1992, Lymphocyte infiltrates as a prognostic variable in female breast cancer, Eur J Cancer, 28A, 859, 10.1016/0959-8049(92)90134-N

Alexe, 2007, High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates, Cancer Res, 67, 10669, 10.1158/0008-5472.CAN-07-0539

Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370

Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat Med, 13, 1050, 10.1038/nm1622

Desmedt, 2008, Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes, Clin Cancer Res, 14, 5158, 10.1158/1078-0432.CCR-07-4756

Loi, 2013, Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98, J Clin Oncol, 31, 860, 10.1200/JCO.2011.41.0902

Mattarollo, 2011, Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors, Cancer Res, 71, 4809, 10.1158/0008-5472.CAN-11-0753

Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3

Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216

Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124

Berns, 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, 12, 395, 10.1016/j.ccr.2007.08.030

Nagata, 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients, Cancer Cell, 6, 117, 10.1016/j.ccr.2004.06.022

Zhang, 2011, Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways, Nat Med, 17, 461, 10.1038/nm.2309

Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, 6, 443, 10.1038/74704

Ignatiadis, 2012, Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis, J Clin Oncol, 30, 1996, 10.1200/JCO.2011.39.5624

Ladoire, 2011, T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival, Br J Cancer, 105, 366, 10.1038/bjc.2011.261

Park, 2010, The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity, Cancer Cell, 18, 160, 10.1016/j.ccr.2010.06.014

Stagg, 2011, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proc Natl Acad Sci USA, 108, 7142, 10.1073/pnas.1016569108

Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093/jnci/djp335

Joensuu, 2006, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer, N Engl J Med, 354, 809, 10.1056/NEJMoa053028

Joensuu, 2009, Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial, J Clin Oncol, 27, 5685, 10.1200/JCO.2008.21.4577

McShane, 2005, Reporting recommendations for tumor marker prognostic studies (REMARK), J Natl Cancer Inst, 97, 1180, 10.1093/jnci/dji237

Grambsch, 1994, Proportional hazards tests and diagnostics based weighted residuals, Biometrika, 81, 515, 10.1093/biomet/81.3.515

Goldhirsch, 2013, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303

Arnould, 2006, Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?, Br J Cancer, 94, 259, 10.1038/sj.bjc.6602930

Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin Cancer Res, 10, 5650, 10.1158/1078-0432.CCR-04-0225

Ladoire, 2011, Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy, Breast Cancer Res Treat, 125, 65, 10.1007/s10549-010-0831-1

Sainz-Perez, 2012, The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences, Cancer Res, 72, 3557, 10.1158/0008-5472.CAN-12-0277

Sommerfeldt, 2006, The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients, Cancer Res, 66, 8258, 10.1158/0008-5472.CAN-05-4201

Balachandran, 2011, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido, Nat Med, 17, 1094, 10.1038/nm.2438

Zitvogel, 2011, Anticancer effects of imatinib via immunostimulation, Nat Med, 17, 1050, 10.1038/nm.2429

Menard, 2009, Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients, Cancer Res, 69, 3563, 10.1158/0008-5472.CAN-08-3807

Knight, 2013, Host immunity contributes to the anti-melanoma activity of BRAF inhibitors, J Clin Invest, 123, 3182, 10.1172/JCI70645

Rakhra, 2010, CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation, Cancer Cell, 18, 485, 10.1016/j.ccr.2010.10.002

Khalili, 2012, Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma, Clin Cancer Res, 18, 5329, 10.1158/1078-0432.CCR-12-1632

Mahmoud, 2011, Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer, J Clin Oncol, 29, 1949, 10.1200/JCO.2010.30.5037

Adams, 2013, Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199., 10.1158/0008-5472.SABCS13-S1-07

Loi, 2013, Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2 + BC), 10.1158/0008-5472.SABCS13-S1-05